Kiora Pharmaceuticals Future Growth
Future criteria checks 5/6
Kiora Pharmaceuticals is forecast to grow earnings and revenue by 20.7% and 39.8% per annum respectively while EPS is expected to grow by 8.4% per annum.
Key information
20.7%
Earnings growth rate
8.4%
EPS growth rate
| Pharmaceuticals earnings growth | 19.8% |
| Revenue growth rate | 39.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 11 Nov 2024 |
Recent future growth updates
Recent updates
Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem
May 21
Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Kiora Pharmaceuticals reports 1H results
Aug 12Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing
Jul 28Kiora Pharmaceuticals prices $5.2M underwritten public offering
Jul 22Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Jul 05EyeGate Pharmaceuticals announces $8M private placement
Jan 06EyeGate surge in premarket as it acquires Panoptes Pharma for $4M
Dec 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | N/A | -21 | N/A | N/A | 2 |
| 12/31/2026 | 1 | -18 | N/A | N/A | 2 |
| 12/31/2025 | 2 | -13 | N/A | N/A | 3 |
| 12/31/2024 | 17 | 5 | N/A | N/A | 3 |
| 9/30/2024 | 16 | 6 | 8 | 8 | N/A |
| 6/30/2024 | 16 | 3 | 5 | 5 | N/A |
| 3/31/2024 | 16 | 2 | 7 | 7 | N/A |
| 12/31/2023 | N/A | -13 | -10 | -10 | N/A |
| 9/30/2023 | N/A | -13 | -9 | -9 | N/A |
| 6/30/2023 | N/A | -12 | -10 | -10 | N/A |
| 3/31/2023 | N/A | -12 | -11 | -11 | N/A |
| 12/31/2022 | N/A | -14 | -10 | -10 | N/A |
| 9/30/2022 | N/A | -17 | -11 | -11 | N/A |
| 6/30/2022 | N/A | -15 | -11 | -11 | N/A |
| 3/31/2022 | N/A | -15 | -11 | -11 | N/A |
| 12/31/2021 | N/A | -14 | -11 | -11 | N/A |
| 9/30/2021 | 0 | -9 | -10 | -9 | N/A |
| 6/30/2021 | 0 | -8 | -9 | -9 | N/A |
| 3/31/2021 | 0 | -7 | -8 | -7 | N/A |
| 12/31/2020 | 0 | -7 | -7 | -7 | N/A |
| 9/30/2020 | N/A | -8 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -10 | -8 | -8 | N/A |
| 3/31/2020 | N/A | -10 | -8 | -8 | N/A |
| 12/31/2019 | 3 | -7 | -8 | -8 | N/A |
| 9/30/2019 | 3 | -7 | -8 | -8 | N/A |
| 6/30/2019 | 3 | -7 | -9 | -8 | N/A |
| 3/31/2019 | 3 | -8 | -9 | -9 | N/A |
| 12/31/2018 | 2 | -11 | -11 | -11 | N/A |
| 9/30/2018 | 2 | -11 | -11 | -10 | N/A |
| 6/30/2018 | 1 | -12 | N/A | -10 | N/A |
| 3/31/2018 | 1 | -13 | N/A | -11 | N/A |
| 12/31/2017 | 0 | -13 | N/A | -6 | N/A |
| 9/30/2017 | 1 | -14 | N/A | -7 | N/A |
| 6/30/2017 | 1 | -13 | N/A | -7 | N/A |
| 3/31/2017 | 1 | -14 | N/A | -7 | N/A |
| 12/31/2016 | 1 | -13 | N/A | -8 | N/A |
| 9/30/2016 | 1 | -12 | N/A | -8 | N/A |
| 6/30/2016 | 0 | -10 | N/A | -6 | N/A |
| 3/31/2016 | N/A | -8 | N/A | -4 | N/A |
| 12/31/2015 | N/A | -17 | N/A | -4 | N/A |
| 9/30/2015 | N/A | -14 | N/A | -3 | N/A |
| 6/30/2015 | N/A | -13 | N/A | -3 | N/A |
| 3/31/2015 | N/A | -12 | N/A | -2 | N/A |
| 12/31/2014 | N/A | -2 | N/A | -1 | N/A |
| 9/30/2014 | N/A | -2 | N/A | -1 | N/A |
| 6/30/2014 | N/A | -3 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KPRX's forecast earnings growth (20.7% per year) is above the savings rate (2.6%).
Earnings vs Market: KPRX's earnings (20.7% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: KPRX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: KPRX's revenue (39.8% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: KPRX's revenue (39.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KPRX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 05:30 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kiora Pharmaceuticals, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Yi Chen | H.C. Wainwright & Co. |
| Matthew Kaplan | Ladenburg Thalmann & Company |